Exclusive Summary

• **Best-in-Class Potential**: Demonstrates stronger T-cell/B-cell binding affinity compared to BMS's Relatlimab and exhibits superior tumor inhibition efficacy even as a monotherapy.
• **Rescuing PD-1 Resistance**: Clinical data shows an ORR of 36.4% in PD-1 resistant melanoma patients (vs. ~15% standard of care), validating its potential to reverse immune resistance.
• **CMC & Manufacturing Excellence**: High production yield (8.1g/L) offers a stable, cost-effective manufacturing process, presenting a significant commercial advantage for potential licensing partners.

Asset Materials

Contact Us for Full Materials